Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"
- PMID: 23704553
- DOI: 10.1126/science.1234089
Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"
Abstract
Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) demonstrates short-term bexarotene treatment clearing preexisting β-amyloid deposits from the brains of APP/PS1ΔE9 mice with low amyloid burden, providing a rationale for repurposing this anticancer agent as an Alzheimer's disease (AD) therapeutic. Using a nearly identical treatment regimen, we were unable to detect any evidence of drug efficacy despite demonstration of target engagement.
Comment in
-
Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".Science. 2013 May 24;340(6135):924-g. doi: 10.1126/science.1234114. Science. 2013. PMID: 23704556 Free PMC article.
Comment on
-
ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.Science. 2012 Mar 23;335(6075):1503-6. doi: 10.1126/science.1217697. Epub 2012 Feb 9. Science. 2012. PMID: 22323736 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous